Bridge to Life Strengthens Presence in Organ Preservation with VitaSmart Acquisition

Introduction

In a significant development within the field of organ preservation, Bridge to Life Ltd. has successfully acquired the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A. This move marks a noteworthy milestone in the company's ongoing commitment to advancing transplant medicine.

Details of the Acquisition

The acquisition agreement not only secures the VitaSmart™ system but also grants Bridge to Life exclusive global trademark rights along with the ability to register the VitaSmart™ name worldwide. This strategic decision allows Bridge to Life to solidify its position as a leader in organ preservation solutions and enhance its enterprise value.

The VitaSmart™ system has shown remarkable efficacy in organ preservation, having been utilized in over 5,000 successful liver perfusions globally using Hypothermic Oxygenated Perfusion (HOPE). This impressive statistic underscores the system's significance in improving the viability of organs for transplantation.

Reaction from Bridge to Life

Don Webber, the CEO and President of Bridge to Life Ltd., expressed excitement regarding this acquisition. He noted that owning the VitaSmart™ system is a game-changer for organ preservation, especially emphasizing its user-friendly design and minimal monitoring requirements. This simplifies the process for clinicians and enhances the implementation of HOPE protocols across medical institutions.

Webber pointed out that the company is in the advanced stages of preparing its submission to the Food and Drug Administration (FDA), aiming to gain approval for the VitaSmart™ system in the United States by the first quarter of 2025. The outcomes from a pivotal study conducted in the U.S. have been highly promising, particularly regarding the primary endpoint of Early Allograft Dysfunction and the significantly shorter length of hospital stay post-transplantation.

Strategic Implications

This acquisition stands to broaden access to the innovative VitaSmart™ technology for U.S. transplant centers and organ procurement organizations. Ultimately, it aims to benefit patients who are in dire need of viable liver transplants. The full ownership of VitaSmart™ not only enhances Bridge to Life's capabilities but also strengthens the company's resolve to meet the increasing global demand for organ preservation solutions.

Importantly, this strategic direction aligns seamlessly with Bridge to Life's mission: improving transplantation outcomes and saving lives.

About Medica S.p.A

Medica S.p.A. is an Italian biomedical company headquartered in the biomedical district of Mirandola, Italy. With a strong international presence, they develop products that boast superior technological innovations dedicated to the purification of blood and water.

About Bridge to Life Ltd

Bridge to Life Ltd. stands out as a market leader in organ preservation solutions, offering renowned products such as Belzer UW®, EasiSlush®, and the VitaSmart™ Machine Perfusion System. The company's focus on quality, innovation, and accessibility enables them to collaborate effectively with leading transplant centers and organ procurement offices worldwide.

This acquisition of the VitaSmart™ system is a pivotal step forward for Bridge to Life as they continue to drive advancements in organ transplantation technologies, thereby contributing to the betterment of healthcare outcomes globally.